News and Trends 7 Feb 2017 Cannabinoid Drug Prolongs the Life of Brain Tumor Patients in Phase II Trials GW Pharmaceuticals announced Phase II results for a cannabinoid drug combination with the potential to increase life expectancy in patients with an aggressive form of brain cancer. GW Pharmaceuticals, one of the coolest biotechs in Cambridge, is developing cannabinoid drugs. Its lead candidate, Epidiolex, could reach the market soon and help treat drug-resistant forms of […] February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2017 British Synbio’s Llama Antibodies recruited for Cancer T-Cell Therapy Isogenica has licensed its synthetic llama antibody library to Maverick Therapeutics, which develops cancer T-cell therapies designed to reduce side effects. Isogenica is a synthetic biology company near Cambridge that develops libraries of therapeutic antibodies. The biotech has granted US-based Maverick Therapeutics licenses to its llamdA VHH antibody library for the discovery, development and commercialization of […] February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 4 Feb 2017 This PhD-Carrying Musician Tells the Story of Life through Music & Video Max Cooper bridges the age-old divide between science and art with a transfixing blend of glitchy electronica, classical music and haunting vocals. I was lucky enough to catch Max Cooper live in Dublin last weekend, during his tour to showcase his latest album, Emergence. Inspired by natural processes and the laws underlying them, Emergence is a tour-de-force of […] February 4, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2017 New British Biotech-Academia Alliance takes on Cardiovascular Disease Heptares Therapeutics and the University of Cambridge have partnered to investigate a novel target for cardiovascular diseases. Heptares Therapeutics, based in London, develops drugs against historically undruggable G protein-coupled receptors (GPCRs). The company has now announced a new research collaboration with the University of Cambridge focusing on a specific GPCR, the apelin receptor. Heptares will support a […] January 31, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 Novo Nordisk will open a €135M Diabetes R&D Center at Oxford University A new research center funded by Novo Nordisk will foster collaborations between its staff and researchers from the University of Oxford. Novo Nordisk and the University of Oxford have announced a collaboration focused on type 2 diabetes research. As part of the effort, the Danish pharma will invest €135M (£115M) over a 10-year period to […] January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 ‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […] January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jan 2017 The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge Cambridge’s image is tied to its Hogwarts-like University and Nobel-hoarding academia, but there’s also an exciting entrepreneurial scene at the cutting edge of technology. We took a look at how big biotech is in the Silicon Fen. Cambridge’s Biotech cluster has an exemplary hive of talent, infrastructure, and capital – enough to create the same vibe […] January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 28 Jan 2017 Microbes Control the Massive Turbine Hall at London’s Tate Modern Philippe Parreno’s Anywhen, occupying the vast hall at Tate Modern, evolves over time in response to the control of tiny living beings. When you enter Tate Modern‘s vast Turbine Hall, you might see lights turning off and on and hear noises coming and going. Without an apparent pattern, sounds and light evolve while families take […] January 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2017 Genetically Engineered Mosquitoes will arrive in India to fight Dengue Oxitec is preparing to start trials testing its solution to reduce the population of disease-transmitting insects in India with its own genetically modified mosquitoes. Oxitec, a spin-out from Oxford University, engineers mosquitoes to reduce their populations in areas where they spread infectious diseases. After success in Brazil and the Cayman Islands, the company is now heading […] January 25, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2017 Smart Nebulizers for Children with Asthma are Underway Vectura has received FDA approval to start testing a smart device to improve asthma therapies in children. Vectura, based in the UK, develops inhaled delivery technology for diseases that affect air tracts, such as cystic fibrosis, or influenza. The company has now received an investigational new drug (IND) approval from the FDA to study a […] January 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2017 New Fundraising Boosts Ultra-Rapid STD Detection Atlas Genetics has raised €32.6M in Series D. The funds will help the company bring ultra-rapid diagnostic tests for STDs to the market. Atlas Genetics, a spin-off from the University of Bath, has closed an impressive €32.6M ($35M) Series D round of fundraising. The funds will support clinical trials, manufacturing and the commercial launch of the company’s second ultra-rapid […] January 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 23 Jan 2017 “Senior Staff Snobbery separates Academia from the Biotech Industry” We caught up with Mark Lowdell, Director of Cellular Therapeutics and the RFH/UCL Cancer Biobank. As one of the few successful scientist-entrepreneurs, he has some ideas about bridging academia and industry in biomedicine. Mark Lowdell was introduced to me by his business partner, RJ Tesi. Tesi co-founded INmune Bio, a promising California-based startup, on Lowdell’s […] January 23, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email